Anti-BRCA2 antibody (ab27976)
Key features and details
- Rabbit polyclonal to BRCA2
- Suitable for: WB
- Reacts with: Human
- Isotype: IgG
Overview
-
Product name
Anti-BRCA2 antibody
See all BRCA2 primary antibodies -
Description
Rabbit polyclonal to BRCA2 -
Host species
Rabbit -
Specificity
ab27976 recognises BRCA2. -
Tested Applications & Species
Application Species WB Human -
Immunogen
Synthetic peptide mapping to the N terminus of human BRCA2.
-
General notes
The Life Science industry has been in the grips of a reproducibility crisis for a number of years. Abcam is leading the way in addressing the problem with our range of recombinant monoclonal antibodies and knockout edited cell lines for gold-standard validation.
One factor contributing to the crisis is the use of antibodies that are not suitable. This can lead to misleading results and the use of incorrect data informing project assumptions and direction. To help address this challenge, we have introduced an application and species grid on our primary antibody datasheets to make it easy to simplify identification of the right antibody for your needs.
Learn more here.
Properties
-
Form
Liquid -
Storage instructions
Shipped at 4°C. Upon delivery aliquot and store at -20°C or -80°C. Avoid repeated freeze / thaw cycles. -
Storage buffer
Preservative: 0.03% Proclin 300
Constituents: PBS, 30% Glycerol (glycerin, glycerine), 0.5% BSA, 0.015% EDTA -
Concentration information loading...
-
Purity
Immunogen affinity purified -
Purification notes
This antibody is peptide affinity purified -
Clonality
Polyclonal -
Isotype
IgG -
Research areas
Associated products
-
Compatible Secondaries
-
Isotype control
-
Recombinant Protein
Applications
The Abpromise guarantee
Our Abpromise guarantee covers the use of ab27976 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Tested applications are guaranteed to work and covered by our Abpromise guarantee.
Predicted to work for this combination of applications and species but not guaranteed.
Does not work for this combination of applications and species.
Application | Species |
---|---|
WB |
Human
|
Application | Abreviews | Notes |
---|---|---|
WB | (2) |
Use a concentration of 1 - 4 µg/ml. Predicted molecular weight: 384 kDa.
|
Notes |
---|
WB
Use a concentration of 1 - 4 µg/ml. Predicted molecular weight: 384 kDa. |
Target
-
Function
Involved in double-strand break repair and/or homologous recombination. Binds RAD51 and potentiates recombinational DNA repair by promoting assembly of RAD51 onto single-stranded DNA (ssDNA). Acts by targeting RAD51 to ssDNA over double-stranded DNA, enabling RAD51 to displace replication protein-A (RPA) from ssDNA and stabilizing RAD51-ssDNA filaments by blocking ATP hydrolysis. May participate in S phase checkpoint activation. Binds selectively to ssDNA, and to ssDNA in tailed duplexes and replication fork structures. -
Tissue specificity
Highest levels of expression in breast and thymus, with slightly lower levels in lung, ovary and spleen. -
Involvement in disease
Defects in BRCA2 are a cause of susceptibility to breast cancer (BC) [MIM:114480]. A common malignancy originating from breast epithelial tissue. Breast neoplasms can be distinguished by their histologic pattern. Invasive ductal carcinoma is by far the most common type. Breast cancer is etiologically and genetically heterogeneous. Important genetic factors have been indicated by familial occurrence and bilateral involvement. Mutations at more than one locus can be involved in different families or even in the same case.
Defects in BRCA2 are the cause of pancreatic cancer type 2 (PNCA2) [MIM:613347]. It is a malignant neoplasm of the pancreas. Tumors can arise from both the exocrine and endocrine portions of the pancreas, but 95% of them develop from the exocrine portion, including the ductal epithelium, acinar cells, connective tissue, and lymphatic tissue.
Defects in BRCA2 are a cause of susceptibility to breast-ovarian cancer familial type 2 (BROVCA2) [MIM:612555]. A condition associated with familial predisposition to cancer of the breast and ovaries. Characteristic features in affected families are an early age of onset of breast cancer (often before age 50), increased chance of bilateral cancers (cancer that develop in both breasts, or both ovaries, independently), frequent occurrence of breast cancer among men, increased incidence of tumors of other specific organs, such as the prostate.
Defects in BRCA2 are the cause of Fanconi anemia complementation group D type 1 (FANCD1) [MIM:605724]. It is a disorder affecting all bone marrow elements and resulting in anemia, leukopenia and thrombopenia. It is associated with cardiac, renal and limb malformations, dermal pigmentary changes, and a predisposition to the development of malignancies. At the cellular level it is associated with hypersensitivity to DNA-damaging agents, chromosomal instability (increased chromosome breakage) and defective DNA repair.
Defects in BRCA2 are a cause of glioma type 3 (GLM3) [MIM:613029]. Gliomas are benign or malignant central nervous system neoplasms derived from glial cells. They comprise astrocytomas and glioblastoma multiforme that are derived from astrocytes, oligodendrogliomas derived from oligodendrocytes and ependymomas derived from ependymocytes. -
Sequence similarities
Contains 8 BRCA2 repeats. -
Post-translational
modificationsPhosphorylated by ATM upon irradiation-induced DNA damage.
Ubiquitinated in the absence of DNA damage; this does not lead to proteasomal degradation. In contrast, ubiquitination in response to DNA damage leads to proteasomal degradation. - Information by UniProt
-
Database links
- Entrez Gene: 675 Human
- Omim: 600185 Human
- SwissProt: P51587 Human
- Unigene: 34012 Human
-
Alternative names
- BRCA 2 antibody
- BRCA1/BRCA2 containing complex subunit 2 antibody
- Brca2 antibody
see all
Images
Datasheets and documents
-
SDS download
-
Datasheet download
References (18)
ab27976 has been referenced in 18 publications.
- Takemoto K et al. Meiosis-Specific C19orf57/4930432K21Rik/BRME1 Modulates Localization of RAD51 and DMC1 to DSBs in Mouse Meiotic Recombination. Cell Rep 31:107686 (2020). WB ; Mouse . PubMed: 32460033
- Adamson AW et al. The RAD52 S346X variant reduces risk of developing breast cancer in carriers of pathogenic germline BRCA2 mutations. Mol Oncol 14:1124-1133 (2020). PubMed: 32175645
- Mohammadian Gol T et al. Depletion of Akt1 and Akt2 Impairs the Repair of Radiation-Induced DNA Double Strand Breaks via Homologous Recombination. Int J Mol Sci 20:N/A (2019). PubMed: 31847370
- Wang F et al. Effect of lanthanum chloride on tumor growth and apoptosis in human ovarian cancer cells and xenograft animal models. Exp Ther Med 16:1143-1148 (2018). PubMed: 30116365
- Maidarti M et al. Inhibition of PTEN activates bovine non-growing follicles in vitro but increases DNA damage and reduces DNA repair response. Hum Reprod N/A:N/A (2018). PubMed: 30521029